DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.message sent
email sent successfully
rareLife solutions 606 Post Road East #397 Westport, CT 06880 |
||
You are receiving this because you have an account on www.oneAMYLOIDOSISvoice.com | ||
To unsubscribe from these emails, click here |
Trusted Resources: Community Center
Online support, community stories, financial assistance
ALECT2 Amyloidosis Support – Facebook
ALECT2 Amyloidosis Support is a Facebook group that was created on 14 May, 2016.
Dorothy Sintas-Abeyta is the patient representative of the ALect2 Alliance. When we have more patients joining with this rare form of amyloidosis, we can merge our efforts to further clinical trials and help each other by sharing knowledge and advocacy.
Related Content
-
videos & visualsHigher Incidence of LECT2 Amyloidosis in Certain Populationshttps://www.youtube.com/watch?v=qdqt6MXt...
-
educationWhat is New in Diagnosis and Management of Light Chain Amyloidosis?Light chain (AL) amyloidosis is caused b...
-
videos & visualsSchmitt: Financial Assistance – ASG AL Webinar 2.24.24 – 5/8https://www.youtube.com/watch?v=lzrMgtOC...
-
news & meetingsWith CRISPR Gene Editing, Unique Treatments Begin to Take off for Rare DiseasesIn February last year, Doherty — now a...
-
educationHereditary Transthyretin-Related AmyloidosisHereditary transthyretin(TTR)-related am...
-
news & meetingsU.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare a...Pfizer Inc. announced today that the U.S...
-
videos & visualsFinancial Assistance Update by Paula Schmitt – ASG Webinar 7.15.23 – 5/7https://www.youtube.com/watch?v=UcxmPgZ7...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.